<DOC>
	<DOCNO>NCT02827448</DOCNO>
	<brief_summary>The purpose study test well NephroCheckTM Test , noninvasive laboratory test perform urine , predict loss kidney function patient heart transplant Left Ventricular Assist Device ( LVAD ) Total Artificial Heart ( TAH ) implant .</brief_summary>
	<brief_title>Effectiveness NephroCheckTM Test Predict Acute Kidney Injury Following Advanced Cardiac Replacement Therapies</brief_title>
	<detailed_description>Current strategy AKI detection rely primarily elevation serum creatinine conjunction diminish urine output . Unfortunately , deviation crude parameter renal function largely insensitive late manifestation AKI , acute tubular necrosis likely already transpire therefore well beyond phase preventive measure may institute . Early phase biomarkers , insulin-like growth factor-binding protein 7 ( `` IGFBP7 '' ) tissue inhibitor metalloproteinases-2 ( `` TIMP-2 '' ) critical mediator G1 cell cycle arrest renal tubular cell early phase cellular injury , provide potential therapeutic window prevent permanent damage . To date , study evaluate efficacy early phase renal biomarkers detect AKI advance heart failure patient undergoing cardiac replacement therapy . Therefore , aim prospective observational study evaluate effectiveness NephroCheckTM predict AKI patient undergo transplant , LVAD implant , TAH implant .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<criteria>Patients receive LVAD heart transplantation Patients unable give consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Left Ventricular Assist Device</keyword>
	<keyword>Heart transplantation</keyword>
	<keyword>Perioperative</keyword>
	<keyword>Acute Kidney Injury</keyword>
	<keyword>Renal</keyword>
	<keyword>Kidney</keyword>
	<keyword>Total Artificial Heart</keyword>
</DOC>